Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 20/20 | 0.60 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.60 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.60 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14038033 | 0.80 | CFTR (0.67) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| SCHEMBL2032993 | 0.80 | CFTR (0.60) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| SCHEMBL12509769 | 0.79 | CFTR (0.68) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| SCHEMBL16168279 | 0.77 | CFTR (0.66) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| SCHEMBL1723714 | 0.77 | CFTR (0.66) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| SCHEMBL12189058 | 0.76 | CFTR (0.83) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| SCHEMBL12189345 | 0.76 | CFTR (0.77) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| SCHEMBL2580213 | 0.76 | CFTR (0.72) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| SCHEMBL30578538 | 0.76 | CFTR (0.72) | CFTRNR1I2ADORA3CYP2C8CYP2C9 | |
| SCHEMBL12509759 | 0.75 | CFTR (0.82) | CFTRNR1I2ADORA3CYP2C8CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4223294-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | Vertex Pharmaceuticals Incorporated (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-3925607-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | Vertex Pharmaceuticals Incorporated (US) | 2021-12-22 | — | — | EP | disclosed |
| EP-3424534-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | Vertex Pharmaceuticals Incorporated (US) | 2019-01-09 | — | — | EP | disclosed |